Kidswell Bio Corporation Stock

Equities

4584

JP3386460004

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-04-19 am EDT 5-day change 1st Jan Change
141 JPY -7.84% Intraday chart for Kidswell Bio Corporation -4.73% +5.22%
Sales 2023 * 2.81B 18.16M Sales 2024 * 2.7B 17.44M Capitalization 5.42B 35.05M
Net income 2023 * -858M -5.55M Net income 2024 * 23M 149K EV / Sales 2023 * 1.93 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 2.01 x
P/E ratio 2023 *
-5.6 x
P/E ratio 2024 *
219 x
Employees 38
Yield 2023 *
-
Yield 2024 *
-
Free-Float 63.72%
More Fundamentals * Assessed data
Dynamic Chart
Kidswell Bio Corporation announced that it has received ¥22.8 million in funding from CVI Investments, Inc. CI
Kidswell Bio Corporation announced that it expects to receive ¥22.8 million in funding from CVI Investments, Inc. CI
Kidswell Bio Corporation(TSE:4584) dropped from S&P Global BMI Index CI
Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million MT
Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody MT
Kidswell Bio Corporation Reports Earnings Results for the Half Year Ended September 30, 2021 CI
Kidswell Bio Corporation(TSE:4584) added to S&P Global BMI Index CI
Gene Techno Science Co.,Ltd. Reports Earnings Results for the Year Ended March 2020 CI
Dojin Group Co., Ltd. entered into a share transfer agreement to acquire Advanced Cell Technology and Engineering Ltd. from Gene Techno Science Co.,Ltd. for ¥0. CI
Gene Techno Science Co.,Ltd. announced that it has received ¥604.852632 million in funding from CVI Investments, Inc. CI
Gene Techno Science Co.,Ltd. announced that it expects to receive ¥604.852632 million in funding from CVI Investments, Inc. CI
Gene Techno Science Enters into Research Agreement with Nagoya University CI
Gene Techno Science Co., Ltd Has Executes A Joint Research Agreement with Oita University CI
Gene Techno Science Co.,Ltd. acquired remaining 94.7% stake in Japan Regenerative Medicine Co., Ltd. from Noritsu Koki Co., Ltd. for ¥0. CI
Gene Techno Science Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020 CI
More news
1 day-7.84%
1 week-4.73%
Current month-6.00%
1 month-5.37%
3 months+9.30%
Current year+5.22%
More quotes
1 week
140.00
Extreme 140
164.00
1 month
135.00
Extreme 135
167.00
Current year
119.00
Extreme 119
167.00
1 year
119.00
Extreme 119
269.00
3 years
119.00
Extreme 119
864.00
5 years
119.00
Extreme 119
1 075.00
10 years
119.00
Extreme 119
1 967.50
More quotes
Managers TitleAgeSince
Chief Administrative Officer - -
Director/Board Member - -
Comptroller/Controller/Auditor 65 18-10-31
Members of the board TitleAgeSince
Director/Board Member 76 18-05-31
Director/Board Member - -
Director/Board Member 38 20-05-31
More insiders
Date Price Change Volume
24-04-19 141 -7.84% 750 400
24-04-18 153 +2.68% 226,700
24-04-17 149 -1.97% 361,800
24-04-16 152 -2.56% 495,900
24-04-15 156 -4.29% 1,171,900

Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT

More quotes
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
153 JPY
Average target price
800 JPY
Spread / Average Target
+422.88%
Consensus